Oramed Reports $1.50 EPS from Non-Operating Gain; Operating Loss Hits $15M
summarizeSummary
Oramed Pharmaceuticals reported its 2025 annual results, showing $2.0 million in revenue and diluted earnings per share of $1.50. While the headline EPS appears strong, the article clarifies that this was primarily driven by a significant $64.016 million non-operating revaluation gain. The company still reported an operating loss of $15.088 million, indicating continued challenges in core operations despite the first material revenue from an HTIT license settlement. This mixed financial picture is critical for investors to understand the true underlying performance. Investors will monitor the company's strategic repositioning, including R&D transfers and new collaborations, to see if these efforts can improve operational profitability in the future.
At the time of this announcement, ORMP was trading at $3.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $132.1M. The 52-week trading range was $1.82 to $3.76. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.